[Therapeutic effect of ticarcillin against severe infection in patients with hematologic malignancy (author's transl)].
Seventy patients with severe infection accompanying hematologic disorders including leukemia and lymphoma were treated with ticarcillin in combination with aminoglycosides and/or cephem derivatives. Of the 58 patients in whom the efficacy could be evaluated, 17 (29%) responded markedly and 22 (38%) moderately, the effective rate being 67%. Side effects attributable to the treatment were noted: rash in 2, fever and rash in 1, vascular pain in 2 (5 and 7 years of age). Renal and hepatic functions were abnormal in 4 each. However, these abnormal findings were not attributed to ticarcillin. These results indicate that ticarcillin is an effective and safe antibiotic for the treatment of severe infection accompanying hematologic malignancy when used in combination with aminoglycosides and/or cephem derivatives.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D010406:Penicillins / Q000627:therapeutic use*; D013982:Ticarcillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D010406:Penicillins; D013982:Ticarcillin